1. Tacrolimus-induced hemolytic uremic syndrome and end-stage renal failure after liver transplantation
- Author
-
Eric Rondeau, K Akposso, Béatrice Mougenot, Nicolas Lerolle, Tibor Ponnelle, Jean-Daniel Sraer, and Jean-Philippe Rerolle
- Subjects
Hemolytic anemia ,Transplantation ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,medicine.medical_treatment ,Liver transplantation ,urologic and male genital diseases ,medicine.disease ,Gastroenterology ,Tacrolimus ,Surgery ,Cyclosporin a ,Internal medicine ,medicine ,Hemodialysis ,Renal biopsy ,business ,Kidney disease - Abstract
Background. Hemolytic uremic syndrome (HUS) is a rare complication in solid organ transplantation. It can be associated with severe hypertension. Several risk factors have been identified including immunosuppressive drugs such as cyclosporin A and, more recently, tacrolimus. Methods. Here we report a case of tacrolimus-induced HUS in a 61-yr-old woman after liver transplantation. Hypertension, microangiopathic anemia and end-stage renal failure occurred 2 yr after liver transplantation. Results. At admission, she had malignant hypertension with a severe hypertensive retinopathy, renal failure (creatininemia: 800 μmol/L) and microangiopathic anemia (Hb: 7.3 g/dL, a low platelet count and elevated lactate dehydrogenase). At renal biopsy, histologic findings were ischemic and sclerotic glomeruli with hyaline thrombi, severe mesangiolysis and interstitial fibrosis. Conclusion. Despite steroid treatment, antihypertensive agents and fresh frozen plasma therapy, end-stage renal failure was observed and chronic hemodialysis treatment was required.
- Published
- 2000
- Full Text
- View/download PDF